ClinicalTrials.gg
TerminatedNCT01131585RELATIONUpdated Aug 30, 2012Results posted

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema

A Phase 3 interventional study of Active laser photocoagulation and Sham injections in Visual Impairment Due to Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Terminated at 36 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
European drug approval.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
29th of 91
128 · median 50
Started
2010
with 4 others
Phase 3
25 of 91
none open now
Registered
22nd of 91
by date
Lead sponsor
21 of 91
Novartis Pharmaceuticals

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 29th largest by enrollment, is one of 5 that started in 2010, is one of 25 in phase 3, and was the 22nd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema. A subgroup of patients with Proliferative Diabetic Retinopathy were included to evaluate the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in this population.

03

Conditions studied

  • Visual Impairment Due to Diabetic Macular Edema

Keywords

  • Diabetic macular edema
  • DME
  • Proliferative diabetic retinopathy
  • PDR
  • ranibizumab
  • laser
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visual acuity impairment caused by macular edema in at least one eye
  • Type 1 or type 2 diabetes mellitus
  • Stable medication of diabetes in past 3 month

Exclusion criteria

Exclusion Criteria:

  • Patients with uncontrolled systemic or ocular diseases
  • Laser photocoagulation in the study eye for the last 3 months
  • Any history of any intraocular surgery in the study eye within the past 3 months
  • Blood pressure > 160/100 mmHg

Other protocol defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Active laser photocoagulation and ranibizumab

    Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment. Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.

    Procedure: Active laser photocoagulation · Drug: Ranibizumab 0.5 mg

  • Active comparator
    Active laser photocoagulation and sham injection

    Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment. Sham intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.

    Procedure: Active laser photocoagulation · Drug: Sham injections

Interventions

  • ProcedureActive laser photocoagulation

    Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.

  • DrugSham injections

    Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.

  • Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.

06

What researchers measure

Primary outcomes

  1. Change in Best-Corrected Visual Acuity (BCVA) From Baseline to Month 12

    Mean change in Best-Corrected Visual Acuity (BCVA) letters at 12 months compared to baseline was measured using Visual acuity (VA). VA accounts for the number of letters a participant can see using Early Treatment Diabetic Retinopathy Study (EDTRS)-like visual acuity testing charts, from a sitting position at a testing distance of 4 meters. BCVA means that the participant's refraction is already taken into account when VA is determined. A higher BCVA number at 12 months in reference to baseline indicates improved BCVA.

    Time frame: 12 months

07

Results

Posted Aug 17, 2012
Limitations and caveats
Early study termination due to European drug approval.

Participant flow

Participants did not complete study due to early termination. Study was terminated because of drug approval.

Participant flow — Overall Study
MilestoneActive Laser Photocoagulation and RanibizumabActive Laser Photocoagulation and Sham Injection
Started8543
Completed00
Not completed8543
Withdrew: Adverse event02
Withdrew: Abnormal laboratory value10
Withdrew: Unsatisfactory therapeutic effect03
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject33
Withdrew: Lost to follow-up01
Withdrew: Administrative problems11
Withdrew: Study termination7832

Outcome measures

PrimaryChange in Best-Corrected Visual Acuity (BCVA) From Baseline to Month 12

Mean change in Best-Corrected Visual Acuity (BCVA) letters at 12 months compared to baseline was measured using Visual acuity (VA). VA accounts for the number of letters a participant can see using Early Treatment Diabetic Retinopathy Study (EDTRS)-like visual acuity testing charts, from a sitting position at a testing distance of 4 meters. BCVA means that the participant's refraction is already taken into account when VA is determined. A higher BCVA number at 12 months in reference to baseline indicates improved BCVA.

Time frame:
12 months
Reported as:
Mean · Letters
Change in Best-Corrected Visual Acuity (BCVA) From Baseline to Month 12
LettersActive Laser Photocoagulation and RanibizumabActive Laser Photocoagulation and Sham Injection
Change in Best-Corrected Visual Acuity (BCVA) From Baseline to Month 126.5 ± 8.61.4 ± 7.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Laser Photocoagulation and Ranibizumab—14/85 (16.5%)32/85 (37.6%)
Active Laser Photocoagulation and Sham Injection—5/43 (11.6%)10/43 (23.3%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventActive Laser Photocoagulation and RanibizumabActive Laser Photocoagulation and Sham Injection
RETINAL DETACHMENT (Fellow eye)Eye disorders0/852/43
HYPOGLYCAEMIAMetabolism and nutrition disorders2/850/43
CORONARY ARTERY DISEASECardiac disorders0/851/43
CORONARY ARTERY STENOSISCardiac disorders0/851/43
VITREOUS HAEMORRHAGE (Fellow eye)Eye disorders0/851/43
CONCOMITANT DISEASE PROGRESSIONGeneral disorders0/851/43
TYPE 1 DIABETES MELLITUSMetabolism and nutrition disorders0/851/43
CHONDROPATHYMusculoskeletal and connective tissue disorders0/851/43
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/851/43
CARDIAC FAILURE CONGESTIVECardiac disorders1/850/43
Most frequent other events
Most frequent other events
EventActive Laser Photocoagulation and RanibizumabActive Laser Photocoagulation and Sham Injection
EYE PAIN (Study eye)Eye disorders13/854/43
NASOPHARYNGITISInfections and infestations13/856/43
HYPERTENSIONVascular disorders4/854/43
EYE IRRITATION (Study eye)Eye disorders5/850/43
LACRIMATION INCREASED (Study eye)Eye disorders5/851/43
HEADACHENervous system disorders5/851/43

Baseline characteristics

Age Continuous
Age Continuous(years)Active Laser Photocoagulation and RanibizumabActive Laser Photocoagulation and Sham InjectionTotal
>=18 years63.5 ± 9.363.5 ± 10.563.5 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Active Laser Photocoagulation and RanibizumabActive Laser Photocoagulation and Sham InjectionTotal
Female321648
Male532780
08

Study locations

36 sites
  • Novartis Investigative Site
    Aschaffenburg, Germany
  • Novartis Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Bonn, Germany
  • Novartis Investigative Site
    Bremen, Germany
  • Novartis Investigative Site
    Chemnitz, Germany
  • Novartis Investigative Site
    Darmstadt, Germany
  • Novartis Investigative Site
    Dessau, Germany
  • Novartis Investigative Site
    Dortmund, Germany
  • Novartis Investigative Site
    Dresden, Germany
  • Novartis Investigative Site
    Eichstaett, Germany
  • Novartis Investigative Site
    Essen, Germany
  • Novartis Investigative Site
    Frankfurt, Germany
  • Novartis Investigative Site
    Freiburg, Germany
  • Novartis Investigative Site
    Giessen, Germany
  • Novartis Investigative Site
    Hamburg, Germany
  • Novartis Investigative Site
    Heidelberg, Germany
  • Novartis Investigative Site
    Karlsruhe, Germany
  • Novartis Investigative Site
    Kiel, Germany
  • Novartis Investigative Site
    Koeln, Germany
  • Novartis Investigative Site
    Landshut, Germany
  • Novartis Investigative Site
    Leipzig, Germany
  • Novartis Investigative Site
    Marburg, Germany
  • Novartis Investigative Site
    Muenchen, Germany
  • Novartis Investigative Site
    Muenster, Germany
  • Novartis Investigative Site
    Mühlheim, Germany
  • Novartis Investigative Site
    München, Germany
  • Novartis Investigative Site
    Münster, Germany
  • Novartis Investigative Site
    Nuernberg, Germany
  • Novartis Investigative Site
    Postdam, Germany
  • Novartis Investigative Site
    Recklinghausen, Germany
  • Novartis Investigative Site
    Regensburg, Germany
  • Novartis Investigative Site
    Rosenheim, Germany
  • Novartis Investigative Site
    Siegburg, Germany
  • Novartis Investigative Site
    Stuttgart, Germany
  • Novartis Investigative Site
    Ulm, Germany
  • Novartis Investigative Site
    Würzburg, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2010
First posted
May 27, 2010
Start
Jun 2010
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Aug 17, 2012
Last update
Aug 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01131585
Responsible party
Sponsor
First posted
May 27, 2010
Start date
Jun 2010
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Aug 17, 2012
Last update
Aug 30, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion